Edwards Lifesciences Corporation Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Edwards Lifesciences Corporation (EW) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $12.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $8.20M.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was -$17.70M, a 282.47% decline year-over-year.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $9.70M.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$4.20M, a 131.82% decline year-over-year.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$44.80M, a 216.06% decline from fiscal 2024.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $38.60M, a 129.76% increase from fiscal 2023.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $16.80M, a 12.50% decline from fiscal 2022.
- Edwards Lifesciences Corporation effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $19.20M, a 38.13% increase from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.00M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $8.20M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$44.80M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$48.30M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$47.30M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | -$17.70M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $38.60M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | -$12.40M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $39.10M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $9.70M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $16.80M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $20.20M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $11.00M 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | -$4.20M 10-Q · filed 2024-04-29 | |||
| 2022-12-31 | $19.20M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $37.40M 10-Q · filed 2023-10-27 | |||
| 2022-06-30 | $27.10M 10-Q · filed 2023-07-28 | |||
| 2022-03-31 | $13.20M 10-Q · filed 2023-04-28 | |||
| 2021-12-31 | $13.90M 10-K · filed 2024-02-12 | |||
| 2021-09-30 | $12.10M 10-Q · filed 2022-10-28 | |||
| 2021-06-30 | $11.60M 10-Q · filed 2022-07-29 | |||
| 2021-03-31 | $14.20M 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | -$20.50M 10-K · filed 2023-02-13 | |||
| 2020-09-30 | -$9.90M 10-Q · filed 2021-10-29 | |||
| 2020-06-30 | -$6.60M 10-Q · filed 2021-07-30 | |||
| 2020-03-31 | -$2.10M 10-Q · filed 2021-04-28 | |||
| 2019-12-31 | -$3.00M 10-K · filed 2022-02-14 | |||
| 2019-09-30 | -$4.40M 10-Q · filed 2020-10-26 | |||
| 2019-06-30 | -$5.20M 10-Q · filed 2020-07-27 | |||
| 2019-03-31 | -$1.30M 10-Q · filed 2020-04-28 | |||
| 2018-12-31 | -$6.50M 10-K · filed 2021-02-12 | |||
| 2017-12-31 | $7.90M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |